<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611321</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI318A201</org_study_id>
    <nct_id>NCT04611321</nct_id>
  </id_info>
  <brief_title>Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of IBI318 in Participants With Advanced Cutaneous Squamous Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1)&#xD;
      in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma&#xD;
      (CSCC), or unresectable locally advanced CSCC that is not amenable to surgery and/or&#xD;
      radiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">August 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate ( evaluated by the independent review committee according to RECIST V1.1; 0-100%). Higher scores mean a better outcome</measure>
    <time_frame>24 months</time_frame>
    <description>RECIST version 1.1 will be used to determine ORR by IRRC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessments of Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>RECIST version 1.1 will be used to determine ORR by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>24 months</time_frame>
    <description>RECIST version 1.1 will be used to determine DOR by investigator and IRRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (progression-free survival)</measure>
    <time_frame>24 months</time_frame>
    <description>RECIST version 1.1 will be used to determine PFS by investigator and IRRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs and SAEs</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the safety and tolerability of IBI318 [Adverse events (AEs), Serious Adverse Events (SAEs) ]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Advanced Cutaneous Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase Ib/II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced CSCC. IBI318 administered intravenously every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.</description>
    <arm_group_label>Phase Ib/II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and willing to sign the ICF.&#xD;
&#xD;
          2. Adults 18 years of age or older.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          4. Life expectancy at least 12 weeks.&#xD;
&#xD;
          5. Adequate organ and bone marrow function.&#xD;
&#xD;
          6. Histologically confirmed diagnosis of invasive CSCC. .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.&#xD;
&#xD;
          2. Any investigational drugs received within 4 weeks prior to the first study treatment.&#xD;
&#xD;
          3. Receive the last dose of anti-tumor therapy within 4 weeks before the first dose of&#xD;
             study therapy.&#xD;
&#xD;
          4. History of autoimmune disease , present active autoimmune disease or inflammatory&#xD;
             diseases&#xD;
&#xD;
          5. Pregnant or nursing females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rong Xing</last_name>
    <phone>17316261509</phone>
    <email>rong.xing@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jin wang</last_name>
      <email>wangjinr@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

